Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 8:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 3,219 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: DNA Clear all
Enrolling by invitation Not applicable Interventional

Strategy for Management of Patients With Hereditary Cancer Syndromes (HCS) in a Rural Environment

NCT07381985
View directory record Official record
Conditions
Hereditary Cancer Syndromes, BRCA1 Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome
Interventions
Longitudinal Cancer Genetics Follow-Up Program
Behavioral
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 31, 2026, 8:24 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum

NCT07811193
View directory record Official record
Conditions
Colorectal Adenocarcinoma
Interventions
VVD-133214, Pembrolizumab
Drug
Lead sponsor
Vividion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Tucson, Arizona • Ann Arbor, Michigan • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 31, 2026, 8:24 AM EDT
Completed Phase 1 Interventional Results available

Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma

NCT03061188
View directory record Official record
Conditions
Advanced Solid Neoplasm, Aggressive Non-Hodgkin Lymphoma, Recurrent Solid Neoplasm, Refractory Mantle Cell Lymphoma, T-Cell Non-Hodgkin Lymphoma, Unresectable Solid Neoplasm
Interventions
Laboratory Biomarker Analysis, Nivolumab, Pharmacological Study, Veliparib
Other · Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Oct 31, 2026, 8:24 AM EDT
Completed Phase 2 Interventional Results available

Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy

NCT00851786
View directory record Official record
Conditions
Herpes Zoster, HIV Infections
Interventions
ZOSTAVAX, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
43
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 31, 2026, 8:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identification of Microbial DNA in Maternal Plasma After PPROM

NCT04318470
View directory record Official record
Conditions
Preterm Rupture of Membranes
Interventions
mNGS
Diagnostic Test
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 31, 2026, 8:24 AM EDT
Active, not recruiting No phase listed Observational

Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma

NCT03896620
View directory record Official record
Conditions
Sarcoma
Interventions
Preoperative RT, Postoperative RT, Chemotherapy, Surgery
Device · Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 31, 2026, 8:24 AM EDT
Completed Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer

NCT00003082
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
monoclonal antibody A27.15, monoclonal antibody E2.3
Biological
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 16, 2010 · Synced Oct 31, 2026, 8:24 AM EDT
Recruiting Phase 1 Interventional

Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi Anemia

NCT07901959
View directory record Official record
Conditions
Fanconi Anemia, Head and Neck Cancer, Squamous Cell Carcinoma, Squamous Cell Cancer of Head and Neck (SCCHN)
Interventions
Metformin, Naproxen Sodium
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Minneapolis, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 31, 2026, 8:24 AM EDT
Completed Phase 2 Interventional Results available

Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy

NCT00416624
View directory record Official record
Conditions
Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
darbepoetin alfa, epoetin alfa, fatigue assessment and management, quality-of-life assessment
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 31, 2026, 8:24 AM EDT
Recruiting Phase 1Phase 2 Interventional

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

NCT06533579
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Burkitt Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Non Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia
Interventions
Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101, Dose Level 4, VNX-101
Genetic
Lead sponsor
Vironexis Biotherapeutics Inc.
Industry
Eligibility
13 Years to 90 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
11
States / cities
Duarte, California • Los Angeles, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 8:24 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis

NCT00001586
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Rituximab, Fludarabine phosphate, Leukemic or stroma cells
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Oct 31, 2026, 8:24 AM EDT
Completed Phase 4 Interventional Results available

Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)

NCT03471624
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
Tenofovir Alafenamide
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Palo Alto, California • San Jose, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 31, 2026, 8:24 AM EDT
Active, not recruiting Phase 1 Interventional

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

NCT02153580
View directory record Official record
Conditions
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia, High Grade B-Cell Lymphoma, Not Otherwise Specified, Post-Transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Hairy Cell Leukemia, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma
Interventions
Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Bendamustine Hydrochloride, Cyclophosphamide, Etoposide, Fludarabine Phosphate
Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 8:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Natural History of Human Papillomavirus (HPV) Infections in Mid-Adult Women (WHIM)

NCT01295242
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
30 Years to 50 Years · Female only
Enrollment
409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 31, 2026, 8:24 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Feasibility of Cell-Free DNA Liquid Biopsy in Screening High-Risk Patients for Lung Cancer

NCT05384769
View directory record Official record
Conditions
Lung Carcinoma
Interventions
Liquid Biopsy, Low Dose Computed Tomography of the Chest, Survey Administration
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
50 Years to 80 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 31, 2026, 8:24 AM EDT
Enrolling by invitation Not applicable Interventional

Use of DNA Testing and Gene Expression Profiling to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression

NCT06336863
View directory record Official record
Conditions
Kidney Transplant Immunosuppression
Interventions
Allosure and TruGraf, Immunosuppression Taper
Diagnostic Test · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 31, 2026, 8:24 AM EDT
Completed Phase 2 Interventional

Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma

NCT00295984
View directory record Official record
Conditions
Sarcoma
Interventions
nicotine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 78 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 31, 2026, 8:24 AM EDT
Completed No phase listed Observational

Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts

NCT00023036
View directory record Official record
Conditions
Sensorineural Hearing Loss, Cytomegalovirus Infection
Interventions
Not listed
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
Up to 99 Years
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 31, 2026, 8:24 AM EDT
Completed Phase 1 Interventional

Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

NCT00004232
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition
Interventions
filgrastim, cyclosporine, methylprednisolone, prednisone, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
10 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 31, 2026, 8:24 AM EDT
Completed Phase 3 Interventional

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)

NCT05630807
View directory record Official record
Conditions
Chronic Hepatitis B, Hepatitis B, Chronic
Interventions
Bepirovirsen, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
981 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
12
States / cities
Chandler, Arizona • Davis, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 31, 2026, 8:24 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Brief Interventions to Increase HPV Vaccine Acceptance in School-based Health Centers

NCT01087164
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
Compliance, Message sidedness
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
11 Years to 15 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 31, 2026, 8:24 AM EDT
Completed Phase 1 Interventional

Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas

NCT01794104
View directory record Official record
Conditions
Neoplasm, Lymphoma
Interventions
LMP400
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Oct 31, 2026, 8:24 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth

NCT00106964
View directory record Official record
Conditions
HIV Infection, Hepatitis B
Interventions
Engerix-B 20 mcg, Engerix-B 40 mcg, Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 24 Years
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 31, 2026, 8:24 AM EDT
Completed No phase listed Observational

Safety and Efficacy of Nicardipine for the Control of Blood Pressure After SAH

NCT00490464
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Intracerebral Hemorrhage
Interventions
Nicardipine and Nipride
Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 70 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 22, 2007 · Synced Oct 31, 2026, 8:24 AM EDT